Phase II news from FierceBiotech
NewsNicOx shares plunge on Pfizer trial failure
Shares of France's NicOx tumbled 38 percent after Pfizer announced that it would not advance their Read more...
SPOTLIGHT: Epix wins $7.5M milestone
Epix Pharmaceuticals says it's due a $7.5 million milestone payment from GSK now that it's launched a Phase IIb trial of a new therapy for Alzheimer's. Researchers say the therapy could one day be Read more...
Pfizer builds plant, creates jobs in Ireland
Pfizer has finally confirmed earlier reports about its plan to Read more...
Roche expands Memory pact
Roche has exercised its option to further develop and commercialize Memory Pharmaceuticals' drug candidate, MEM 3454, for various neurological and psychiatric disorders. Memory gets a $6 million Read more...
Critical Therapeutics, Cornerstone to merge
Critical Therapeutics is merging with Cornerstone Read more...
$117M venture firm takes flight in Europe
A group of Elan veterans in Ireland have launched a €75 million ($117 million) venture fund for life sciences companies. Fountain Healthcare Partners, based in Dublin, plans to sink anywhere from Read more...
ALSO NOTED: Analysts predict trouble for second-gen Rituxan; Sucampo earns $50M on FDA approval;and much more...
> Jim Reddoch, a biotech analyst with Friedman, Billings & Ramsey, is raising some interesting questions about Genentech's second-generation Read more...
Mass. biotechs ripe for buyouts
Recently, GSK forked over $720 million for Sirtris Pharmaceuticals and Japan's Takeda made an Read more...
Dyax forges $231M development deal for DX-88
Cubist Pharmaceuticals has agreed to pay Dyax $15 million upfront and up to $216.5 million more in potential milestone payments for collaboration rights to Dyax's experimental therapy for the Read more...
Argos garners $35.2M in third round
TVM Capital led a hefty $35.2 million third round of venture capital for Colorado's Argos Therapeutics. The funding will be used to support Argos' Phase II trial of Arcelis immunotherapy drug Read more...
| Press ReleasesPRESS RELEASE: Nabi Biopharmaceuticals Announces Successful Completion of NicVAX Phase 2b Trial Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Read more... PRESS RELEASE: Anesiva Initiates New Phase 2 Trial of Adlea Anesiva Initiates New Phase 2 Trial of Adlea for Pain Relief Following Knee Replacement Surgery Adlea May Provide Pain Relief Without Opiate-Like Side Effects For Several Months Following a Single Read more... PRESS RELEASE: Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis Results Show Improvements in RA Signs and Symptoms Compared to Placebo Trubion Pharmaceuticals today Read more... |
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight